公开(公告)号：WO2012150042A1

公开(公告)日：2012-11-08

申请号：PCT/EP2012/001926

申请日：2012-05-04

Applicant: CELLZOME AG ,  GLAXO GROUP LIMITED ,  FREEMAN, Jay ,  HARRISON, John ,  KRUSE, Ulrich ,  SHEPHERD, Robert John ,  WILSON, David Matthew ,  WOODROW, Michael David

Inventor： FREEMAN, Jay ,  HARRISON, John ,  KRUSE, Ulrich ,  SHEPHERD, Robert John ,  WILSON, David Matthew ,  WOODROW, Michael David

IPC: C07D295/135 ,  A61K31/198 ,  A61P35/00

CPC classification number: C07D295/135

Abstract: The present invention relates to immobilization compounds, immobilization products and preparations thereof as well as methods and uses for the identification of histone demethylase interacting compounds or for the purification or identification of histone demethylase proteins.

Abstract translation: 本发明涉及固定化合物，固定产物及其制备方法以及用于鉴定组蛋白去甲基化酶相互作用化合物或用于纯化或鉴定组蛋白脱甲基酶蛋白质的方法和用途。

公开(公告)号：WO2012123119A1

公开(公告)日：2012-09-20

申请号：PCT/EP2012/001149

申请日：2012-03-14

Applicant: CELLZOME AG ,  DREWES, Gerard ,  JOBERTY, Gerard

Inventor： DREWES, Gerard ,  JOBERTY, Gerard

IPC: G01N33/50

CPC classification number: G01N33/6875 ,  G01N2500/04

Abstract: The present invention relates to methods for the identification of proteins capable of interacting with a given histone tail as well as of compounds interacting with said proteins.

Abstract translation: 本发明涉及用于鉴定能够与给定的组蛋白尾部以及与所述蛋白质相互作用的化合物相互作用的蛋白质的方法。

公开(公告)号：WO2012016704A1

公开(公告)日：2012-02-09

申请号：PCT/EP2011/003920

申请日：2011-08-04

Applicant: CELLZOME AG ,  HARRISON, John ,  ADDISON, Glynn ,  RAMSDEN, Nigel ,  DREWES, Gerard

Inventor： HARRISON, John ,  ADDISON, Glynn ,  RAMSDEN, Nigel ,  DREWES, Gerard

IPC: G01N33/573 ,  C12Q1/48

CPC classification number: C07H19/16 ,  C12Q1/48 ,  G01N33/573 ,  G01N2333/91011

Abstract: The present invention relates to immobilization compounds, immobilization products and preparations thereof as well as methods and uses for the identification of methyltransferase interacting compounds or for the purification or identification of methyltransferase proteins.

Abstract translation: 本发明涉及固定化合物，固定产物及其制备方法以及用于鉴定甲基转移酶相互作用化合物或用于纯化或鉴定甲基转移酶蛋白质的方法和用途。

公开(公告)号：WO2012010240A1

公开(公告)日：2012-01-26

申请号：PCT/EP2011/003055

申请日：2011-06-20

Applicant: CELLZOME AG ,  DREWES, Gerard ,  HOPF, Carsten ,  KRUSE, Ulrich ,  NEUBAUER, Gitte

Inventor： DREWES, Gerard ,  HOPF, Carsten ,  KRUSE, Ulrich ,  NEUBAUER, Gitte

IPC: C12Q1/48 ,  G01N33/50

CPC classification number: G01N33/573 ,  G01N33/5088 ,  G01N2333/91215 ,  G01N2500/00

Abstract: The invention relates to a method for evaluation of a compound-target interaction in vivo, comprising the steps of administering the compound to an animal, taking a body fluid sample of the animal, determining the concentration of the compound in the body fluid sample, taking a cellular sample of the animal containing the target, preparing a protein preparation of said cellular sample, providing an immobilised ligand capable of binding to the target, contacting the protein preparation with the immobilised ligand under conditions allowing the formation of a complex between the immobilised ligand and the target, determining the amount of complexes formed in step, and correlating the amount of complexes with the concentration of the compound in the body fluid sample.

Abstract translation: 本发明涉及一种用于评价体内化合物 - 靶相互作用的方法，包括以下步骤：向动物施用化合物，服用动物的体液样品，测定体液样品中化合物的浓度，取 制备含有该靶标的动物的细胞样品，制备所述细胞样品的蛋白质制剂，提供能够结合靶标的固定化配体，使蛋白质制剂与固定的配体在允许在固定化配体之间形成复合物的条件下接触 和靶标，确定步骤中形成的络合物的量，并且将复合物的量与体液样品中化合物的浓度相关联。

公开(公告)号：WO2011095363A1

公开(公告)日：2011-08-11

申请号：PCT/EP2011/000581

申请日：2011-02-08

Applicant: SYGNIS BIOSCIENCE GMBH & CO KG ,  SCHNEIDER, Armin ,  SPOELGEN, Robert ,  DITTGEN, Tanjew ,  PITZER, Claudia ,  PLAAS, Christian

Inventor： SCHNEIDER, Armin ,  SPOELGEN, Robert ,  DITTGEN, Tanjew ,  PITZER, Claudia ,  PLAAS, Christian

IPC: G01N33/50

CPC classification number: G01N33/5023 ,  C12Q1/6883 ,  C12Q2600/136 ,  C12Q2600/156

Abstract: Provided are cell based methods to identify memory modulating compounds based on the assessment of KIBRA expression. These methods are also suitable to uncover memory related pathways. The methods comprise the contacting of test compounds with cultured cells and the subsequent assessment of modulation of the KIBRA expression within the cells.

Abstract translation: 提供基于基于KIBRA表达的评估来鉴定记忆调节化合物的基于细胞的方法。 这些方法也适用于揭示记忆相关途径。 所述方法包括测试化合物与培养细胞的接触以及随后评估细胞内KIBRA表达的调节。

公开(公告)号：WO2011066987A1

公开(公告)日：2011-06-09

申请号：PCT/EP2010/007358

申请日：2010-12-03

Applicant: SYGNIS BIOSCIENCE GMBH & CO. KG ,  SCHNEIDER, Armin ,  SPOELGEN, Robert ,  MEYER, Annette

Inventor： SCHNEIDER, Armin ,  SPOELGEN, Robert ,  MEYER, Annette

IPC: G01N33/50

CPC classification number: G01N33/5058

Abstract: The present invention relates to methods for quantifying neurogenesis in vivo. These method combine the isolation of purified nuclei from the brain tissue, the specific labelling of the nuclei of newly generated neurons thereof, and the counting of these nuclei. Density sedimentation is suitable for the separation of the nuclei of the cells from the complex debris of the brain tissue. As a matter of course the markers which are used for that identification have to be presented on the surface of the nuclei or within the nuclei. FACS analysis is the preferred method for counting the differentially labelled nuclei of proliferating neurons and the ones of other neural cells.

Abstract translation: 本发明涉及用于定量体内神经发生的方法。 这些方法结合了纯化的核从脑组织的分离，其新产生的神经元核的特异性标记，以及这些细胞核的计数。 密度沉降适用于从脑组织的复杂碎片分离细胞核。 当然，用于该鉴定的标记物必须呈现在细胞核的表面或核内。 FACS分析是计数增殖神经元和其他神经细胞的差异标记细胞核的首选方法。

公开(公告)号：WO2011038933A2

公开(公告)日：2011-04-07

申请号：PCT/EP2010/006020

申请日：2010-10-01

Applicant: UNIVERSITÄT DUISBURG-ESSEN ,  RHEINISCHE FRIEDRICH-WILHELMS-UNIVERSITÄT BONN ,  ROGGENDORF, Michael ,  EIS-HÜBINGER, Anna-Maria ,  KRAUSS, Jürgen ,  SCHNEWEIS, Karl Eduard ,  ARNDT, Michaela ,  KRAWCZYK, Adalbert ,  EXNER, Evelyn ,  DÄUMER, Martin

Inventor： ROGGENDORF, Michael ,  EIS-HÜBINGER, Anna-Maria ,  KRAUSS, Jürgen ,  SCHNEWEIS, Karl Eduard ,  ARNDT, Michaela ,  KRAWCZYK, Adalbert ,  EXNER, Evelyn ,  DÄUMER, Martin

IPC: A61K31/22

CPC classification number: C07K16/087 ,  A61K39/00 ,  A61K2039/505 ,  C07K2317/24 ,  C07K2317/34 ,  C07K2317/54 ,  C07K2317/55 ,  C07K2317/565 ,  C07K2317/567 ,  C07K2317/76 ,  C07K2317/92

Abstract: The invention relates to an anti-HSV antibody as defined in the claims, a pharmaceutical composition comprising of an effective amount of the said antibody, an expression vector comprising of a nucleotide sequence which encodes the said antibody, a host cell comprising of the said nucleotide sequence, a hybridoma cell capable of producing the said antibody and the use of the said antibody as a drug, in particular to use for the manufacture of a drug for the prophylactical or therapeutical treatment of HSV-associated diseases in a subject; as defined in the claims.

Abstract translation: 本发明涉及权利要求中定义的抗HSV抗体，包含有效量的所述抗体的药物组合物，包含编码所述抗体的核苷酸序列的表达载体， 包含所述核苷酸序列的宿主细胞，能够产生所述抗体的杂交瘤细胞以及所述抗体作为药物的用途，特别是用于制备用于预防性或治疗性治疗HSV相关的药物 对象中的疾病; 如权利要求中所定义。

公开(公告)号：WO2010136192A1

公开(公告)日：2010-12-02

申请号：PCT/EP2010/003201

申请日：2010-05-26

Applicant: ALEPOR GMBH & CO. KG ,  JACKSON, David B. ,  STEIN, Martin ,  VOSS, Hartmut ,  BROCK, Stephan ,  DANES, Christopher G. ,  SOOD, Anil

Inventor： JACKSON, David B. ,  STEIN, Martin ,  VOSS, Hartmut ,  BROCK, Stephan ,  DANES, Christopher G. ,  SOOD, Anil

IPC: C12Q1/68

CPC classification number: G01N33/57492 ,  C12N15/1138 ,  C12Q1/6886 ,  C12Q2600/106 ,  G01N33/5011 ,  G01N33/5041 ,  G01N33/57415 ,  G01N33/746 ,  G01N2800/52

Abstract: There is disclosed a molecular composition(s) of a novel tissue protective erythropoietin (EPO) binding receptor protein complex, termed NEPOR. Presence of NEPOR components on a tumour allows EPO to impinge on the survival of associated cells thereby enhancing tumour progression and negatively effecting patient survival. Presence of NEPOR represents a prognostic bio marker for poorer patient outcome. Thus, methods are provided for stratifying patients having a tumour as suitable (i.e. NEPOR not present) or non-suitable (i.e., NEPOR present) for EPO treatment, comprising: (a) isolating a tissue sample from an individual who is receiving or is a candidate for receiving erythropoietin, (b) determining the level of expression of the NEPOR gene(s) (mRNA) and/or the presence of the NEPOR gene product (protein) from the isolated tissue, and (c) correlating the presence of an NEPOR gene expression product or the presence of NEPOR protein to a physiological response to the treatment with erythropoietin. Furthermore, by disclosing the molecular compositions of NEPOR species, there are disclosed methods for rationally identifying/designing NEPOR modulating therapeutics. Methods also are provided for treating neurological insults such as stroke (via enhancement of NEPOR activity) and cancer (via down-regulation of cyto- protective signaling from NEPOR).

Abstract translation: 公开了一种称为NEPOR的新型组织保护促红细胞生成素（EPO）结合受体蛋白复合物的分子组成。 在肿瘤上存在NEPOR成分允许EPO影响相关细胞的存活，从而增强肿瘤进展并对患者的存活产生负面影响。 NEPOR的存在代表较差的患者结局的预后生物标志物。 因此，提供了用于对具有适合的肿瘤（即NEPOR不存在）或不适合（即，存在的NEPOR）的患者进行EPO治疗的分层方法，其包括：（a）从接受或正在接受的个体分离组织样品 接受促红细胞生成素的候选物，（b）从分离的组织中确定NEPOR基因（mRNA）的表达水平和/或NEPOR基因产物（蛋白质）的存在，以及（c） NEPOR基因表达产物或NEPOR蛋白的存在对促红细胞生成素治疗的生理反应。 此外，通过公开NEPOR种类的分子组成，公开了合理鉴定/设计NEPOR调节治疗剂的方法。 还提供用于治疗诸如中风（通过增强NEPOR活性）和癌症（通过下调NEPOR的细胞保护性信号传导）的神经学损伤的方法。

公开(公告)号：WO2010127878A2

公开(公告)日：2010-11-11

申请号：PCT/EP2010/002861

申请日：2010-05-10

Applicant: SYGNIS BIOSCIENCE GMBH & CO. KG ,  SCHNEIDER, Armin ,  MORARU, Anja ,  KRÜGER, Carola ,  LAAGE, Rico

Inventor： SCHNEIDER, Armin ,  MORARU, Anja ,  KRÜGER, Carola ,  LAAGE, Rico

IPC: A61K31/4184

CPC classification number: A61K31/4184

Abstract: The present invention relates to the use of thiabendazole and derivatives thereof for the preparation of a pharmaceutical composition for treating and/or preventing a neuronal condition where there is a need of neuroprotection and/or neurcregeneration. Tiie invention furthermore relates to the use of thiabendazole and derivatives thereof for the in vitro differentiation of neuronal stem cells and the use of such pre-treated cells for stem cell therapy of neurological conditions.

Abstract translation: 本发明涉及噻苯达唑及其衍生物在制备用于治疗和/或预防需要神经保护和/或神经再生的神经元状况的药物组合物中的应用。 蒂恩发明还涉及噻苯达唑及其衍生物用于神经元干细胞体外分化的用途，以及这些预处理细胞用于神经系统疾病干细胞治疗的用途。

公开(公告)号：WO2008138578A2

公开(公告)日：2008-11-20

申请号：PCT/EP2008/003789

申请日：2008-05-09

Applicant: MEDICAL PROGNOSIS INSTITUTE ,  KNUDSEN, Steen

Inventor： KNUDSEN, Steen

IPC: C12Q1/68

CPC classification number: C12Q1/6886 ,  C12Q2600/106 ,  C12Q2600/118 ,  C12Q2600/178

Abstract: The present invention features methods, kits, and devices for predicting the sensitivity of a patient to a compound or medical treatment. The invention also features methods for identifying gene biomarkers whose expression correlates to treatment sensitivity or resistance within a patient population or subpopulation.

Abstract translation: 本发明的特征在于用于预测患者对化合物或医疗治疗的敏感性的方法，试剂盒和装置。 本发明还涉及用于鉴定其表达与患者群体或亚群体内的治疗敏感性或抗性相关的基因生物标志物的方法。